Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Angiogenesis
Erschienen in: Angiogenesis 2/2020

09.11.2019 | Review Paper

Reconciling the distinct roles of angiogenic/anti-angiogenic factors in the placenta and maternal circulation of normal and pathological pregnancies

verfasst von: Anandita Umapathy, Lawrence W. Chamley, Joanna L. James

Erschienen in: Angiogenesis | Ausgabe 2/2020

Einloggen, um Zugang zu erhalten

Abstract

A branched vascular network is crucial to placental development and is dependent on factors such as vascular endothelial growth factor (VEGF), placental growth factor (PlGF), angiopoietin-1 (Ang-1), angiopoietin-2 (Ang-2), soluble fms-like tyrosine kinase-1 (sFlt-1) and soluble endoglin (sEng) to regulate blood vessel growth. Imbalances in these factors can lead to aberrant placental vascular development. Throughout pregnancy, these factors are also released into the maternal circulation to aid in adapting the maternal cardiovascular system to pregnancy. Increased secretion of anti-angiogenic factors can lead to the development of an anti-angiogenic state in the mother and contribute to the development of pregnancy pathologies such as pre-eclampsia and foetal growth restriction (FGR). Thus, what are commonly referred to as ‘angiogenic factors’ have distinct functions in the maternal and placental circulations making this a misnomer. Indeed, technical issues in this field such as assay methodology and lack of data considering different placental cell types mean that the physiological roles of these factors in the maternal and placental circulations are frequently muddled in the literature. This review aims to (1) unpick the distinct roles of factors that influence placental vascular development and separate these from the roles of the same factors within the maternal circulation in normal pregnancy and (2) critically assess how imbalances may contribute to the distinct pathophysiological mechanisms underlying pregnancy disorders. Together, this critical assessment of the field endeavours to improve our ability to accurately use these factors as predictive/diagnostic biomarkers in the future.
Literatur
1.
Boyd JD, Hamilton WJ (1970) The human placenta. Heffer, Cambridge
2.
Pereira RD, De Long NE, Wang RC, Yazdi FT, Holloway AC, Raha S (2015) Angiogenesis in the placenta: the role of reactive oxygen species signaling. Biomed Res Int 2015:814543PubMedPubMedCentral
3.
Alfaidy N, Hoffmann P, Boufettal H, Samouh N, Aboussaouira T, Benharouga M, Feige JJ, Brouillet S (2014) The multiple roles of EG-VEGF/PROK1 in normal and pathological placental angiogenesis. Biomed Res Int 2014:451906PubMedPubMedCentral
4.
5.
Cuffe JS, Holland O, Salomon C, Rice GE, Perkins AV (2017) Placental derived biomarkers of pregnancy disorders. Placenta 54:104–110PubMed
6.
Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S, Libermann TA, Morgan JP, Sellke FW, Stillman IE, Epstein FH, Sukhatme VP, Karumanchi SA (2003) Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Investig 111:649–658PubMedPubMedCentral
7.
Brownbill P, McKeeman GC, Brockelsby JC, Crocker IP, Sibley CP (2007) Vasoactive and permeability effects of vascular endothelial growth factor-165 in the term in vitro dually perfused human placental lobule. Endocrinology 148:4734–4744PubMed
8.
Kendall RL, Thomas KA (1993) Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proc Natl Acad Sci USA 90:10705–10709PubMedPubMedCentral
9.
Yáñez-Mó M, Siljander PR, Andreu Z, Bedina Zavec A, Borràs FE, Buzas EI, Buzas K, Casal E, Cappello F, Carvalho J et al (2015) Biological properties of extracellular vesicles and their physiological functions. J Extracell Vesicle 4:27066
10.
Akercan F, Cirpan T, Terek MC, Ozcakir HT, Giray G, Sagol S, Karadadas N (2008) The immunohistochemical evaluation of VEGF in placenta biopsies of pregnancies complicated by preeclampsia. Arch Gynecol Obstet 277:109–114PubMed
11.
Andraweera PH, Dekker GA, Roberts CT (2012) The vascular endothelial growth factor family in adverse pregnancy outcomes. Hum Reprod Update 18:436–457PubMed
12.
Lyall F, Young A, Boswell F, Kingdom J, Greer IA (1997) Placental expression of vascular endothelial growth factor in placentae from pregnancies complicated by pre-eclampsia and intrauterine growth restriction does not support placental hypoxia at delivery. Placenta 18:269–276PubMed
13.
Sgambati E, Marini M, Zappoli Thyrion GD, Parretti E, Mello G, Orlando C, Simi L, Tricarico C, Gheri G, Brizzi E (2004) VEGF expression in the placenta from pregnancies complicated by hypertensive disorders. BJOG 111:564–570PubMed
14.
Sezer SD, Küçük M, Döger FK, Yüksel H, Odabaşı AR, Türkmen MK, Cakmak BÇ, Ömürlü İK, Kınaş MG (2013) VEGF, PIGF and HIF-1α in placentas of early- and late-onset pre-eclamptic patients. Gynecol Endocrinol 29:797–800PubMed
15.
Kim S, Roh J, Park C (2016) Immunohistochemistry for pathologists: protocols, pitfalls, and tips. J Pathol Transl Med 50:411PubMedPubMedCentral
16.
Zhou Y, McMaster M, Woo K, Janatpour M, Perry J, Karpanen T, Alitalo K, Damsky C, Fisher SJ (2002) Vascular endothelial growth factor ligands and receptors that regulate human cytotrophoblast survival are dysregulated in severe preeclampsia and hemolysis, elevated liver enzymes, and low platelets syndrome. Am J Pathol 160:1405–1423PubMedPubMedCentral
17.
Cooper JC, Sharkey AM, Charnock-Jones DS, Palmer CR, Smith SK (1996) VEGF mRNA levels in placentae from pregnancies complicated by pre-eclampsia. Br J Obstet Gynaecol 103:1191–1196PubMed
18.
Jarvenpaa J, Vuoristo JT, Savolainen E, Ukkola O, Vaskivuo T, Ryynanen M (2007) Altered expression of angiogenesis-related placental genes in pre-eclampsia associated with intrauterine growth restriction. Gynecol Endocrinol 23:351–355PubMed
19.
Ranheim T, Cathrine Staff A, Henriksen T (2001) VEGF mRNA is unaltered in decidual and placental tissues in preeclampsia at delivery. Acta Obstet Gynecol Scand 80:93–98PubMed
20.
Soker S, Svahn CM, Neufeld G (1993) Vascular endothelial growth factor is inactivated by binding to alpha 2-macroglobulin and the binding is inhibited by heparin. J Biol Chem 268:7685–7691PubMed
21.
Witzenbichler B, Maisonpierre PC, Jones P, Yancopoulos GD, Isner JM (1998) Chemotactic properties of angiopoietin-1 and-2, ligands for the endothelial-specific receptor tyrosine kinase Tie2. J Biol Chem 273:18514–18521PubMed
22.
Ferrara N, Davis-Smyth T (1997) The biology of vascular endothelial growth factor. Endocr Rev 18:4–25PubMed
23.
24.
Arroyo JA, Winn VD (2008) Vasculogenesis and angiogenesis in the IUGR placenta. Semin Perinatol 32:172–177PubMed
25.
Rigano S, Bozzo M, Ferrazzi E, Bellotti M, Battaglia FC, Galan HL (2001) Early and persistent reduction in umbilical vein blood flow in the growth-restricted fetus: a longitudinal study. Obstet Gynecol 185:834–838
26.
Burton GJ, Woods AW, Jauniaux E, Kingdom J (2009) Rheological and physiological consequences of conversion of the maternal spiral arteries for uteroplacental blood flow during human pregnancy. Placenta 30:473–482PubMedPubMedCentral
27.
Glazier JD, Cetin I, Perugino G, Ronzoni S, Grey AM, Mahendran D, Marconi AM, Pardi G, Sibley CP (1997) Association between the activity of the system A amino acid transporter in the microvillous plasma membrane of the human placenta and severity of fetal compromise in intrauterine growth restriction. Pediatr Res 42:514–519PubMed
28.
Jansson T, Scholtbach V, Powell TL (1998) Placental transport of leucine and lysine is reduced in intrauterine growth restriction. Pediatr Res 44:532–537PubMed
29.
Krebs C, Macara LM, Leiser R, Bowman AW, Greer IA, Kingdom JC (1996) Intrauterine growth restriction with absent end-diastolic flow velocity in the umbilical artery is associated with maldevelopment of the placental terminal villous tree. Obstet Gynecol 175:1534–1542
30.
Zygmunt M, Herr F, Münstedt K, Lang U, Liang OD (2003) Angiogenesis and vasculogenesis in pregnancy. Eur J Obstet Gynecol Reprod Biol 110:S1–S18
31.
Roex A, Nikpoor P, van Eerd E, Hodyl N, Dekker G (2012) Serial plotting on customised fundal height charts results in doubling of the antenatal detection of small for gestational age fetuses in nulliparous women. Aust NZ J Obstet Gynecol 52:78–82
32.
Gardosi J, Madurasinghe V, Williams M, Malik A, Francis A (2013) Maternal and fetal risk factors for stillbirth: population based study. BMJ 346:f108PubMedPubMedCentral
33.
34.
Raymond D, Peterson E (2011) A critical review of early-onset and late-onset preeclampsia. Obstet Gynecol Surv 66:497–506PubMed
35.
Crovetto F, Crispi F, Scazzocchio E, Mercade I, Meler E, Figueras F, Gratacos E (2014) First-trimester screening for early and late small-for-gestational-age neonates using maternal serum biochemistry, blood pressure and uterine artery Doppler. Ultrasound Obstet Gynecol 43:34–40PubMed
36.
Wang A, Rana S, Karumanchi SA (2009) Preeclampsia: the role of angiogenic factors in its pathogenesis. Physiology (Bethesda) 24:147–158
37.
Meekins JW, Pijnenborg R, Hanssens M, McFadyen IR, van Asshe A (1994) A study of placental bed spiral arteries and trophoblast invasion in normal and severe pre-eclamptic pregnancies. Br J Obstet Gynaecol 101:669–674PubMed
38.
Lau SY, Guild S, Barrett CJ, Chen Q, McCowan L, Jordan V, Chamley LW (2013) Tumor necrosis factor-alpha, interleukin-6, and interleukin-10 levels are altered in preeclampsia: a systematic review and meta-analysis. Am J Reprod Immunol 70:412–427PubMed
39.
40.
Mayhew TM, Wijesekara J, Baker PN, Ong SS (2004) Morphometric evidence that villous development and fetoplacental angiogenesis are compromised by intrauterine growth restriction but not by pre-eclampsia. Placenta 25:829–833PubMed
41.
Eastwood K, Hunter AJ, Patterson CC, Mc Cance DR, Young IS, Holmes VA (2018) Placental vascularization indices and prediction of pre-eclampsia in high-risk women. Placenta 70:53–59PubMed
42.
Reynolds LP, Redmer DA (2001) Angiogenesis in the placenta. Biol Reprod 64:1033–1040PubMed
43.
Mihu CM, Suşman S, Ciucă DR, Mihu D, Costin N (2009) Aspects of placental morphogenesis and angiogenesis. Rom J Morphol Embryol 50:549–557PubMed
44.
Kaufmann P, Mayhew TM, Charnock-Jones DS (2004) Aspects of human fetoplacental vasculogenesis and angiogenesis. II. Changes during normal pregnancy. Placenta 25:114–126PubMed
45.
Regnault T, Galan HL, Parker TA, Anthony RV (2002) Placental development in normal and compromised pregnancies—a review. Placenta 23:S119–S129PubMed
46.
Wang Y (2010) Vascular biology of the placenta. In Colloquium series on integrated systems physiology: from molecule to function. Morgan & Claypool Life Sci  2:1–98
47.
Tseng JJ, Chou MM, Hsieh YT, Wen MC, Ho ES, Hsu SL (2006) Differential expression of vascular endothelial growth factor, placenta growth factor and their receptors in placentae from pregnancies complicated by placenta accreta. Placenta 27:70–78PubMed
48.
Ahmad S, Ahmed A (2004) Elevated placental soluble vascular endothelial growth factor receptor-1 inhibits angiogenesis in preeclampsia. Circ Res 95:884–891PubMed
49.
Erez O, Romero R, Espinoza J, Fu W, Todem D, Kusanovic JP, Gotsch F, Edwin S, Nien JK, Chaiworapongsa T (2008) The change in concentrations of angiogenic and anti-angiogenic factors in maternal plasma between the first and second trimesters in risk assessment for the subsequent development of preeclampsia and small-for-gestational age. J Matern Fetal Neonatal Med 21:279–287PubMedPubMedCentral
50.
Kusanovic JP, Romero R, Chaiworapongsa T, Erez O, Mittal P, Vaisbuch E, Mazaki-Tovi S, Gotsch F, Edwin SS, Gomez R (2009) A prospective cohort study of the value of maternal plasma concentrations of angiogenic and anti-angiogenic factors in early pregnancy and midtrimester in the identification of patients destined to develop preeclampsia. J Matern Fetal Neonatal Med 22:1021–1038PubMedPubMedCentral
51.
Levine RJ, Maynard SE, Qian C, Lim K, England LJ, Yu KF, Schisterman EF, Thadhani R, Sachs BP, Epstein FH (2004) Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 350:672–683PubMed
52.
Lim JH, Kim SY, Park SY, Yang JH, Kim MY, Ryu HM (2008) Effective prediction of preeclampsia by a combined ratio of angiogenesis-related factors. Obstset Gynecol 111:1403–1409
53.
Hoeller A, Ehrlich L, Golic M, Herse F, Perschel FH, Siwetz M, Henrich W, Dechend R, Huppertz B, Verlohren S (2017) Placental expression of sFlt-1 and PlGF in early preeclampsia vs. early IUGR vs. age-matched healthy pregnancies. Hypertens Pregnancy 36:151–160PubMed
54.
Shibata E, Rajakumar A, Powers RW, Larkin RW, Gilmour C, Bodnar LM, Crombleholme WR, Ness RB, Roberts JM, Hubel CA (2005) Soluble fms-like tyrosine kinase 1 is increased in preeclampsia but not in normotensive pregnancies with small-for-gestational-age neonates: relationship to circulating placental growth factor. J Clin Endocrinol Metab 90:4895–4903PubMed
55.
Khalil A, Muttukrishna S, Harrington K, Jauniaux E (2008) Effect of antihypertensive therapy with alpha methyldopa on levels of angiogenic factors in pregnancies with hypertensive disorders. PLoS ONE 3:e2766PubMedPubMedCentral
56.
Ferrara N (2004) Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 25:581–611PubMed
57.
Barut F, Barut A, Gun BD, Kandemir NO, Harma MI, Harma M, Aktunc E, Ozdamar SO (2010) Intrauterine growth restriction and placental angiogenesis. Diagn Pathol 5:24PubMedPubMedCentral
58.
Bates DO, MacMillan PP, Manjaly JG, Qiu Y, Hudson SJ, Bevan HS, Hunter AJ, Soothill PW, Read M, Donaldson LF (2006) The endogenous anti-angiogenic family of splice variants of VEGF, VEGFxxxb, are down-regulated in pre-eclamptic placentae at term. Clin Sci 110:575–585
59.
Geva E, Ginzinger DG, Zaloudek CJ, Moore DH, Byrne A, Jaffe RB (2002) Human placental vascular development: vasculogenic and angiogenic (branching and nonbranching) transformation is regulated by vascular endothelial growth factor-A, angiopoietin-1, and angiopoietin-2. J Clin Endocrinol Metab 87:4213–4224PubMed
60.
Dunk C, Shams M, Nijjar S, Rhaman M, Qiu Y, Bussolati B, Ahmed A (2000) Angiopoietin-1 and angiopoietin-2 activate trophoblast Tie-2 to promote growth and migration during placental development. Am J Pathol 156:2185–2199PubMedPubMedCentral
61.
Kappou D, Sifakis S, Androutsopoulos V, Konstantinidou A, Spandidos DA, Papantoniou N (2014) Placental mRNA expression of angiopoietins (Ang)-1, Ang-2 and their receptor Tie-2 is altered in pregnancies complicated by preeclampsia. Placenta 35:718–723PubMed
62.
Lobov IB, Brooks PC, Lang RA (2002) Angiopoietin-2 displays VEGF-dependent modulation of capillary structure and endothelial cell survival in vivo. Proc Natl Acad Sci USA 99:11205–11210PubMedPubMedCentral
63.
Whitley GS, Dash P, Ayling LJ, Prefumo F, Thilaganathan B, Cartwright JE (2007) Increased apoptosis in first trimester extravillous trophoblasts from pregnancies at higher risk of developing preeclampsia. Am J Pathol 170:1903–1909
64.
Charolidi N, Host AJ, Ashton S, Tryfonos Z, Leslie K, Thilaganathan B, Cartwright JE, Whitley GS (2018) First trimester placental endothelial cells from pregnancies with abnormal uterine artery Doppler are more sensitive to apoptotic stimuli. Lab Investig 99:411–420PubMed
65.
Chappell JC, Taylor SM, Ferrara N, Bautch VL (2009) Local guidance of emerging vessel sprouts requires soluble Flt-1. Dev Cell 17:377–386PubMedPubMedCentral
66.
Kumasawa K, Ikawa M, Kidoya H, Hasuwa H, Saito-Fujita T, Morioka Y, Takakura N, Kimura T, Okabe M (2011) Pravastatin induces placental growth factor (PGF) and ameliorates preeclampsia in a mouse model. Proc Natl Acad Sci USA 108:1451–1455PubMed
67.
Nikuei P, Rajaei M, Malekzadeh K, Nejatizadeh A, Mohseni F, Poordarvishi F (2017) Expression of placental growth factor mRNA in preeclampsia. Int J Reprod Biomed (Yazd) 15:169
68.
Record M (2014) Intercellular communication by exosomes in placenta: a possible role in cell fusion? Placenta 35:297–302PubMed
69.
Boeldt DS, Bird IM (2017) Vascular adaptation in pregnancy and endothelial dysfunction in preeclampsia. J Endocrinol 232:R27PubMed
70.
Tsiakkas A, Duvdevani N, Wright A, Wright D, Nicolaides KH (2015) Serum soluble fms-like tyrosine kinase-1 in the three trimesters of pregnancy: effects of maternal characteristics and medical history. Ultrasound Obstet Gynecol 45:584–590PubMed
71.
Pang L, Wei Z, Li O, Huang R, Qin J, Chen H, Fan X, Chen Z (2013) An increase in vascular endothelial growth factor (VEGF) and VEGF soluble receptor-1 (sFlt-1) are associated with early recurrent spontaneous abortion. PLoS ONE 8:e75759PubMedPubMedCentral
72.
73.
Nadar SK, Karalis I, Al Yemeni E, Blann AD, Lip GY (2005) Plasma markers of angiogenesis in pregnancy induced hypertension. Thromb Haemost 94:1071–1076PubMed
74.
El-Sokkary MS, El-Refaie TA, Mostafa NBH, Elaassar MMS (2017) Maternal serum vascular endothelial growth factor in patients with preeclampsia. Egypt J Hosp Med 69:1634–1640
75.
Saffer C, Olson G, Boggess KA, Beyerlein R, Eubank C, Sibai BM, NORMALS Study Group (2013) Determination of placental growth factor (PlGF) levels in healthy pregnant women without signs or symptoms of preeclampsia. Pregnancy Hypertens 3:124–132PubMed
76.
De Vivo A, Baviera G, Giordano D, Todarello G, Corrado F, D’anna R (2008) Endoglin, PlGF and sFlt-1 as markers for predicting pre-eclampsia. Acta Obstet Gynecol Scand 87:837–842PubMed
77.
Crispi F, Llurba E, Dominguez C, Martín-Gallán P, Cabero L, Gratacos E (2008) Predictive value of angiogenic factors and uterine artery Doppler for early- versus late-onset pre-eclampsia and intrauterine growth restriction. Ultrasound Obstet Gynecol 31:303–309PubMed
78.
Kim S, Ryu H, Yang J, Kim M, Han J, Kim J, Chung J, Park S, Lee M, Kim D (2007) Increased sFlt-1 to PlGF ratio in women who subsequently develop preeclampsia. J Korean Med Sci 22:873–877PubMedPubMedCentral
79.
Tsatsaris V, Goffin F, Munaut C, Brichant J, Pignon M, Noel A, Schaaps J, Cabrol D, Frankenne F, Foidart J (2003) Overexpression of the soluble vascular endothelial growth factor receptor in preeclamptic patients: pathophysiological consequences. J Clin Endocrinol Metab 88:5555–5563PubMed
80.
Leinonen E, Wathén K, Alfthan H, Ylikorkala O, Andersson S, Stenman U, Vuorela P (2010) Maternal serum angiopoietin-1 and -2 and tie-2 in early pregnancy ending in preeclampsia or intrauterine growth retardation. J Clin Endocrinol Metab 95:126–133PubMed
81.
Lai J, Syngelaki A, Poon LC, Nucci M, Nicolaides KH (2013) Maternal serum soluble endoglin at 30-33 weeks in the prediction of preeclampsia. Fetal Diagn Ther 33:149–155PubMed
82.
Chaiworapongsa T, Romero R, Kusanovic JP, Mittal P, Kim SK, Gotsch F, Than NG, Mazaki-Tovi S, Vaisbuch E, Erez O (2010) Plasma soluble endoglin concentration in pre-eclampsia is associated with an increased impedance to flow in the maternal and fetal circulations. Ultrasound Obstet Gynecol 35:155–162PubMedPubMedCentral
83.
Nanjo S, Minami S, Mizoguchi M, Yamamoto M, Yahata T, Toujima S, Shiro M, Kobayashi A, Muragaki Y, Ino K (2017) Levels of serum-circulating angiogenic factors within 1 week prior to delivery are closely related to conditions of pregnant women with pre-eclampsia, gestational hypertension, and/or fetal growth restriction. J Obstet Gynaecol Res 43:1805–1814PubMed
84.
Esser S, Wolburg K, Wolburg H, Breier G, Kurzchalia T, Risau W (1998) Vascular endothelial growth factor induces endothelial fenestrations in vitro. J Cell Biol 140:947–959PubMedPubMedCentral
85.
Roberts JM, Rajakumar A (2009) Preeclampsia and soluble fms-like tyrosine kinase 1. J Clin Endocrinol Metab 94(7):2252–2254PubMedPubMedCentral
86.
McAllister KA, Lennon F, Bowles-Biesecker B, McKinnon WC, Helmbold EA, Markel DS, Jackson CE, Guttmacher AE, Pericak-Vance MA, Marchuk DA (1994) Genetic heterogeneity in hereditary haemorrhagic telangiectasia: possible correlation with clinical phenotype. J Med Genet 31:927–932PubMedPubMedCentral
87.
Sela S, Itin A, Natanson-Yaron S, Greenfield C, Goldman-Wohl D, Yagel S, Keshet E (2008) A novel human-specific soluble vascular endothelial growth factor receptor 1: cell type-specific splicing and implications to vascular endothelial growth factor homeostasis and preeclampsia. Circ Res 102:1566–1574PubMed
88.
Eremina V, Sood M, Haigh J, Nagy A, Lajoie G, Ferrara N, Gerber H, Kikkawa Y, Miner JH, Quaggin SE (2003) Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J Clin Investig 111:707–716PubMedPubMedCentral
89.
Bills VL, Salmon AH, Harper SJ, Overton TG, Neal CR, Jeffery B, Soothill PW, Bates DO (2011) Impaired vascular permeability regulation caused by the VEGF165b splice variant in pre-eclampsia. BJOG 118:1253–1261PubMed
90.
Baker PN, Davidge ST, Barankiewicz J, Roberts JM (1996) Plasma of preeclamptic women stimulates and then inhibits endothelial prostacyclin. Hypertension 27:56–61PubMed
91.
Toporsian M, Gros R, Kabir MG, Vera S, Govindaraju K, Eidelman DH, Husain M, Letarte M (2005) A role for endoglin in coupling eNOS activity and regulating vascular tone revealed in hereditary hemorrhagic telangiectasia. Circ Res 96:684–692PubMed
92.
Venkatesha S, Toporsian M, Lam C, Hanai J, Mammoto T, Kim YM, Bdolah Y, Lim K, Yuan H, Libermann TA (2006) Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med 12:642PubMed
93.
Voron T, Marcheteau E, Pernot S, Colussi O, Tartour E, Taieb J, Terme M (2014) Control of the immune response by pro-angiogenic factors. Front Oncol 4:70PubMedPubMedCentral
94.
Takahashi A, Kono K, Ichihara F, Sugai H, Fujii H, Matsumoto Y (2004) Vascular endothelial growth factor inhibits maturation of dendritic cells induced by lipopolysaccharide, but not by proinflammatory cytokines. Cancer Immunol Immunother 53:543–550PubMed
95.
Shojaei F, Wu X, Zhong C, Yu L, Liang X, Yao J, Blanchard D, Bais C, Peale FV, Van Bruggen N (2007) Bv8 regulates myeloid-cell-dependent tumour angiogenesis. Nature 450:825PubMed
96.
Rana S, Schnettler WT, Powe C, Wenger J, Salahuddin S, Cerdeira AS, Verlohren S, Perschel FH, Arany Z, Lim K (2013) Clinical characterization and outcomes of preeclampsia with normal angiogenic profile. Hypertens Pregnancy 32:189–201PubMedPubMedCentral
97.
Szukiewicz D, Szewczyk G, Watroba M, Kurowska E, Maslinski S (2005) Isolated placental vessel response to vascular endothelial growth factor and placenta growth factor in normal and growth-restricted pregnancy. Gynecol Obstet Investig 59:102–107
98.
Hirokoshi K, Maeshima Y, Kobayashi K, Matsuura E, Sugiyama H, Yamasaki Y, Masuyama H, Hiramatsu Y, Makino H (2005) Increase of serum angiopoietin-2 during pregnancy is suppressed in women with preeclampsia. Am J Hypertens 18:1181–1188PubMed
99.
Baffert F, Thurston G, Rochon-Duck M, Le T, Brekken R, McDonald DM (2004) Age-related changes in vascular endothelial growth factor dependency and angiopoietin-1-induced plasticity of adult blood vessels. Circ Res 94:984–992PubMed
100.
Thurston G, Wang Q, Baffert F, Rudge J, Papadopoulos N, Jean-Guillaume D, Wiegand S, Yancopoulos GD, McDonald DM (2005) Angiopoietin 1 causes vessel enlargement, without angiogenic sprouting, during a critical developmental period. Development 132:3317–3326PubMed
101.
Thurston G, Suri C, Smith K, McClain J, Sato TN, Yancopoulos GD, McDonald DM (1999) Leakage-resistant blood vessels in mice transgenically overexpressing angiopoietin-1. Science 286:2511–2514PubMed
102.
Kim I, Kim J, Ryu YS, Liu M, Koh GY (2000) Tumor necrosis factor-α upregulates angiopoietin-2 in human umbilical vein endothelial cells. Biochem Biophys Res Commun 269:361–365PubMed
103.
Wang Y, Tasevski V, Wallace EM, Gallery ED, Morris JM (2007) Reduced maternal serum concentrations of angiopoietin-2 in the first trimester precede intrauterine growth restriction associated with placental insufficiency. BJOG 114:1427–1431PubMed
104.
Hanahan D, Folkman J (1996) Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86:353–364PubMed
105.
Nasu K, Fujisawa K, Nishida Y, Kai S, Sugano T, Miyakawa I, Tateishi Y (2003) Expression of collagen XVIII mRNA and protein in human umbilical vein and placenta. Reprod Fertil Dev 15:107–114PubMed
106.
Yamaguchi N, Anand-Apte B, Lee M, Sasaki T, Fukai N, Shapiro R, Que I, Lowik C, Timpl R, Olsen BR (1999) Endostatin inhibits VEGF-induced endothelial cell migration and tumor growth independently of zinc binding. EMBO J 18:4414–4423PubMedPubMedCentral
107.
Hirtenlehner K, Pollheimer J, Lichtenberger C, Wolschek MF, Zeisler H, Husslein P, Knöfler M (2003) Elevated serum concentrations of the angiogenesis inhibitor endostatin in preeclamptic women. J Soc Gynecol Investig 10:412–417PubMed
108.
Wikström A, Larsson A, Åkerud H, Olovsson M (2009) Increased circulating levels of the antiangiogenic factor endostatin in early-onset but not late-onset preeclampsia. Reprod Sci 16:995–1000PubMed
109.
Conde-Agudelo A, Papageorghiou AT, Kennedy SH, Villar J (2013) Novel biomarkers for predicting intrauterine growth restriction: a systematic review and meta-analysis. BJOG 120:681–694PubMed
110.
Agrawal S, Cerdeira AS, Redman C, Vatish M (2017) Meta-analysis and systematic review to assess the role of soluble FMS-like tyrosine kinase-1 and placenta growth factor ratio in prediction of preeclampsia: the SaPPPhirE study. Hypertension 71:306–316PubMed
111.
Alahakoon TI, Zhang W, Trudinger BJ, Lee VW (2014) Discordant clinical presentations of preeclampsia and intrauterine fetal growth restriction with similar pro- and anti-angiogenic profiles. J Matern Fetal Neonatal Med 27:1854–1859PubMed
112.
Verlohren S, Herraiz I, Lapaire O, Schlembach D, Zeisler H, Calda P, Sabria J, Markfeld-Erol F, Galindo A, Schoofs K (2014) New gestational phase-specific cutoff values for the use of the soluble fms-like tyrosine kinase-1/placental growth factor ratio as a diagnostic test for preeclampsia. Hypertension 63:346–352PubMed
113.
Akolekar R, Syngelaki A, Sarquis R, Zvanca M, Nicolaides KH (2011) Prediction of early, intermediate and late pre-eclampsia from maternal factors, biophysical and biochemical markers at 11–13 weeks. Prenat Diagn 31:66–74PubMed
114.
Sovio U, Gaccioli F, Hund M, Charnock-Jones DS, Smith GC (2017) 155: Screening for late fetal growth restriction using ultrasound and the sFlt-1:PlGF ratio. AJOG 216:S104
115.
Li Z, Zhang Y, Ying Ma J, Kapoun AM, Shao Q, Kerr I, Lam A, O’Young G, Sannajust F, Stathis P (2007) Recombinant vascular endothelial growth factor 121 attenuates hypertension and improves kidney damage in a rat model of preeclampsia. Hypertension 50:686–692PubMed
116.
Gilbert JS, Verzwyvelt J, Colson D, Arany M, Karumanchi SA, Granger JP (2010) Recombinant vascular endothelial growth factor 121 infusion lowers blood pressure and improves renal function in rats with placentalischemia-induced hypertension. Hypertension 55:380–385PubMed
117.
Carr DJ, Wallace JM, Aitken RP, Milne JS, Martin JF, Zachary IC, Peebles DM, David AL (2016) Peri- and postnatal effects of prenatal adenoviral VEGF gene therapy in growth-restricted sheep. Biol Reprod 94:142PubMed
118.
Carr DJ, Wallace JM, Aitken RP, Milne JS, Mehta V, Martin JF, Zachary IC, Peebles DM, David AL (2014) Uteroplacental adenovirus vascular endothelial growth factor gene therapy increases fetal growth velocity in growth-restricted sheep pregnancies. Hum Gene Ther 25:375–384PubMedPubMedCentral
119.
Vaughan OR, Rossi CA, Ginsberg Y, White A, Hristova M, Sebire NJ, Martin J, Zachary IC, Peebles DM, David AL (2018) Perinatal and long-term effects of maternal uterine artery adenoviral VEGF-A165 gene therapy in the growth-restricted guinea pig fetus. Am J Physiol Regul Integr Comp Physiol 315:R344–R353PubMed
120.
Spencer R, Ambler G, Brodszki J, Diemert A, Figueras F, Gratacós E, Hansson SR, Hecher K, Huertas-Ceballos A, Marlow N (2017) EVERREST prospective study: a 6-year prospective study to define the clinical and biological characteristics of pregnancies affected by severe early onset fetal growth restriction. BMC Pregnancy Childbirth 17:43PubMedPubMedCentral
Metadaten
Titel
Reconciling the distinct roles of angiogenic/anti-angiogenic factors in the placenta and maternal circulation of normal and pathological pregnancies
verfasst von
Anandita Umapathy
Lawrence W. Chamley
Joanna L. James
Publikationsdatum
09.11.2019
Verlag
Springer Netherlands
Erschienen in
Angiogenesis / Ausgabe 2/2020
Print ISSN: 0969-6970
Elektronische ISSN: 1573-7209
DOI
https://doi.org/10.1007/s10456-019-09694-w

Weitere Artikel der Ausgabe 2/2020

Angiogenesis 2/2020 Zur Ausgabe

Perspective

Positive and negative feedback mechanisms controlling tip/stalk cell identity during sprouting angiogenesis

Correction

Correction to: Rho-mediated activation of PI(4)P5K and lipid second messengers is necessary for promotion of angiogenesis by Semaphorin 4D

Retraction Note

Retraction Note to: Semaphorin 4D cooperates with VEGF to promote angiogenesis and tumor progression

Original Paper

BMP10-mediated ALK1 signaling is continuously required for vascular development and maintenance

Brief Communication

Stabilization of myeloid-derived HIFs promotes vascular regeneration in retinal ischemia

Original Paper

The protein tyrosine phosphatase PTPRJ/DEP-1 contributes to the regulation of the Notch-signaling pathway and sprouting angiogenesis

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

25.04.2024 | Hypotonie | Nachrichten

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 | Hypertonie | Nachrichten

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 | Nierenkarzinom | Nachrichten

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 | NSCLC | Nachrichten

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC
weitere anzeigen

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise